A CNIC team has designed a gene therapy-based treatment that could transform the approach to arrhythmogenic cardiomyopathy type 5 (ARVC5), a rare and fatal genetic disease that particularly affects young men.
A team from the National Center for Cardiovascular Research (CNIC) has developed an innovative gene therapy that could transform the treatment of arrhythmogenic cardiomyopathy type 5 (ARVC5), a rare and extremely lethal genetic heart disease. This disease, which is particularly devastating in young men, currently has no cure, and available treatments only offer palliative solutions.
The study, led by Dr. Enrique Lara-Pezzi , leader of the Molecular Regulation of Heart Failure group at the CNIC and researcher at CIBERCV , has shown that introducing a healthy version of the TMEM43 gene directly into heart cells significantly improves heart function and prolongs the survival of mice affected by the disease.
The research is the result of more than 10 years of collaboration between a clinical team, led by Dr. Pablo García-Pavía , from the Puerta de Hierro Majadahonda Hospital and head of the Hereditary Cardiomyopathies group at the CNIC, and a basic-translational group, led by Dr. Lara-Pezzi, which has allowed us to better understand this disease and offer effective alternatives for its treatment.
After the first patients with this disease were identified in Spain at Puerta de Hierro Hospital, the collaboration between both groups led to the creation of the first model replicating the disease in animals in 2019. Now, researchers have gone a step further by developing a therapy to treat this condition.
ARVC5 is caused by mutations in the TMEM43 gene and is characterized by severe arrhythmias and sudden death. It is particularly aggressive in young men, whose average life expectancy is less than 42 years. Although implantable cardioverter-defibrillators (ICDs) are used to prevent sudden death, there are no treatments to slow the progression of the disease.
In this study, published in the journal Circulation Research , CNIC researchers have designed a gene therapy based on adeno-associated viral (AAV) vectors, a safe platform for use in humans, to introduce a functional copy of the TMEM43 gene into the cardiac cells of mice.
The results obtained are promising : the therapy not only improved heart contraction and reduced fibrosis, but also significantly prolonged the lifespan of the treated mice. A single dose of the treatment was sufficient to prevent the electrical and structural alterations typical of the disease.
“This breakthrough brings us closer to a potential cure for this devastating disease,” explains Dr. Laura Lalaguna , first author of the study. “By increasing the amount of healthy TMEM43 protein in the heart, we were able to counteract the toxic effects of the mutated protein, improving heart function and slowing disease progression.”
Furthermore, adds Dr. Enrique Lara-Pezzi, this work opens up new therapeutic possibilities for other inherited cardiomyopathies, a group of diseases for which current heart failure treatments are often ineffective. “AAV-based gene therapy has great potential to offer targeted and curative solutions, not only for ARVC5, but also for other inherited cardiac disorders.”
This study marks a key step in the search for more effective treatments for rare diseases and could transform the prognosis of affected patients, alleviating the burden of inherited heart disease and reducing the need for constant medical monitoring, which would benefit both patients and healthcare systems.
This project has been funded by the Pathfinder Cardiogenomics program of the European Innovation Council (project DCM-NEXT; 101115416) and by grants PID2021-124629OB-I00, TED2021-129774B-C22, PLEC2022-009235, awarded by the Ministry of Science and Innovation (MCIN/ AEI/10.13039/501100011033), by the European Union through NextGenerationEU/PRTR (“Spain’s Recovery, Transformation and Resilience Plan”) and by ERDF .
Leave a Reply